Latvia

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for... 2011-06-07

BMI View: Our view that Latvia will return only weak pharmaceutical market growth in 2011 remains firmly in play. The performance of this market remains indelibly tied to the country's... 2011-05-17

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2011-03-08

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical &... 2011-01-13

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2010-12-16

BMI View: The prospect of the Latvian government requesting drug producers reduce their prices is a further deterrent for pharmaceutical companies operating in the country. This issue,... 2010-11-29